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The lung clearance index (LCI) measured by multiple breath washout (MBW) is accepted as 
a surrogate endpoint for clinical trials (1) and may be a useful test to clinically monitor lung 
function in children and adults with cystic fibrosis (CF). The review of evidence for the use of 
LCI in CF clinical trials published in 2014 concluded that LCI has good clinimetric properties 
including strong intra-test repeatability, strong correlation with validated measure of lung 
function (FEV1), quality of life and pulmonary exacerbation in both child and adult groups (2). 
LCI is responsive to modulator therapy and is predictive of future lung function (1,3). In 
health, the longitudinal evolution of LCI declines from infancy to early childhood, stabilises in 
early childhood to adulthood and slowly increases thereafter with age (4). The 2014 review 
concluded that LCI has a low variability between repeated sessions (i.e. stable coefficient of 
variation [CV%]) with one study reporting a coefficient of reproducibility (COR) of 0.96 for 
measurements 24 hours apart (using MBN2W and an Exhalyzer Da) (5). There have been 
more limited data on the longer term inter-test repeatability within the CF population, thus the 
interpretation of a clinically meaningful change is more difficult. Determination of the inter-
test repeatability is very important to inform the treatment effect that can be considered 
clinically significant (i.e. larger than the difference in LCI seen between repeat 
measurements without intervention or change in clinical status). Recent published data may 
go some way to address these gaps in the literature (Table 1).  
Using MBWSF6 methodology, the COR of repeated measurements approximately 8 
months apart was 1.40 (6,7). Using MBN2W the % difference between repeated 
measurements ranging from 3 to 12 months apart, ranged from 17-25% with an average 
COR of 2.00, with good agreement reported between the 2 most recent publications in the 
current issue of JCF (Green et al and Svedberg et al) (3,8-10). Significantly, some studies 
(using MBN2W) indicate that LCI variability is driven by disease state (8,10) with increasing 
LCI variability as the LCI value increases (both within and between session). This evidence 
supports expressing LCI variability as a relative and not an actual change and has 
implications for powering a study to detect a change in LCI, i.e. base the sample size on the 
meaningful change expected for that disease severity.  
It is also now established that the differences between MBW methodologies must be 
considered when interpreting the study results. In vivo and in vitro studies have 
demonstrated significant differences between results derived from different MBN2W devices 
and when different tracer gases are applied. Differences in results from different MBN2W 
devices are driven by the measurement algorithms used in the software results. Therefore, 
results are not interchangeable until there is harmonisation of measurement algorithms (11). 
On comparing the different tracer gas methods, MBN2W overestimates FRC and there is 
clear bias towards disproportionately higher LCI at higher mean values of LCI (i.e. more 
severe disease) compared with MBWSF6 (12,13). Importantly, there is also evidence to 
show that tissue N2 contribution impacts on washout, causing error in indirect measurement 
of N2 which is more pronounced in longer washouts (i.e. patients with higher LCI values) 
(13,14). This evidence may provide some explanation for the greater inter-test variability 
seen in MBN2W tests compared with SF6.  
Whilst there is greater inter-test variability seen in LCI using MBN2W, the relative 
change in LCI was comparable to that seen in FEV1 % predicted (10). Furthermore, inter-
visit repeatability data for MBWSF6 is limited to one study and further research is needed, 
particularly where MBN2W with 100% O2 is not a suitable approach in the infant age range. 
Decreased permeation in poorly ventilated lungs may also be a potential limitation of 
MBWSF6 methodology which also requires further study (12). Relating to MBN2W, further 
study of the impact of the application of N2 tissue excretion corrections, the use of earlier test 
end-points and the use of using end-tidal concentrations versus volume averaged phase III 
expired concentrations to identify the LCI end-point, may reduce variability and improve 
agreement between results from different devices using different inert gases.  
To facilitate such comparisons, future studies could describe inter-visit repeatability 
as a percentage change, in addition to a statistic (e.g. %CV, the intra-class correlation 
coefficient (ICC), the limits of agreement (LOA) from Bland–Altman plots, or COR); with 
caution using those where it is assumed that the measurement variability is independent of 
its magnitude (LOA and COR).  
 The differences between results from MBW technologies complicate the transition of 
MBW from the research setting to clinical care and necessitate standardisation of specific 
devices and protocols for multicentre use. Feasibility data summarised in 2014 review 
indicated variable success rates with MBW testing ranging from 24% to 100%. Not 
surprisingly, most challenges have been encountered in the infant and pre-school age range 
due to issues relating to patient co-operation, the requirement for patient interface 
adjustment, a sedation protocol and the associated logistics (2). Assessment of the most 
recent feasibility data in CF (Table 1) indicates improvements in successful application of 
MBW testing in the research and clinical setting, with success rates ranging from 73-99% 
across a wide age range. Notably, in the current issue of JCF, Stahl et al demonstrate high 
success rates in the application of MBWSF6 in sedated infants and preschool children with 
CF across 3 centres without prior MBW experience (15). Moreover, Downing et al assessed 
the feasibility of performing MBW in the routine outpatient setting in a group of children with 
respiratory disease (including patients with CF), reporting success rates comparable to those 
in the research setting (73%) (16). Reflecting on reasons for test exclusion, results from all 
studies indicate that patient factors (e.g. lack of cooperation) can influence success rates as 
much as technical or quality issues, especially in the younger age groups. To optimise 
feasibility, there is a need for continued adherence to the developed standardised training 
protocols (led by the North American central over reading centre; 
http://lab.research.sickkids.ca/ratjen/mbw-centre/) for operator training, certification and 
optimal testing approach, specific to the age group of interest (infants, pre-school, school 
age and adults). Ongoing consideration of operator role, knowledge and experience as well 
as external links to central over reading centres for support and quality control, will facilitate 
continuous learning and adherence to the standardisation document for MBW testing (17).  
The most recent MBN2W data indicates more variability in LCI than previously 
appreciated and support the reporting of percent change and the consideration of age and 
severity of target populations when powering a study based on LCI. Further longitudinal data 
on MBWSF6 is required, especially in infants and young children. LCI is currently adopted in 
commercial interventional clinical trials. These will provide further important data from 
treatment and placebo groups on treatment response and inter-test repeatability. 
Improvements in testing success rates are likely the result of the emergence of key 
consensus guidance and work from clinical trial committees to standardise testing methods, 
training, data analysis and quality control (17-19), efforts which have strengthened the 
feasibility of LCI. Time constraints may continue to be a limiting factor in the clinical setting, 
particularly with MBN2W where washout times are longer. Exploration of end of test cut-off 
concentrations earlier in the washout may improve feasibility of this test in the clinical as well 
as the research setting.  
Some key questions that remain concern a clear definition of the patient subgroup 
where MBW would be indicated (i.e. where LCI would offer additional information to routine 
lung function testing) and how clinical decisions are made on the basis of LCI. A longitudinal 
multicentre, randomised blinded controlled trial to assess the impact of LCI on treatment 
decisions in CF patients would determine the utility of LCI and would be a major step in the 
transition of LCI from the research into the clinical setting.
Table 1: Inter-test variability and feasibility of LCI in CF 
 
Inter-test variability 
N and subject type Apparatus Gas N measurements (time 
between) 
Results Statistic Author 
77 CF Children 
aged 
2.5-6 
years  
Exhalyzer Da N2 2 (24 hours apart) 
 
2-5 (at 1, 3, 6 ,9 & 12 
months) 
+/- 17% 
 
+/- 25% 
 
 
2.00 
 
 
Percentage change 
 
Average 
Percentage change 
 
Average COR 
(10) 
25 CF Children 
aged 
6-17 
years 
Exhalyzer Da N2 At least 2 visit (3 months 
apart) 
7.4% 
 
+/- 17% 
Mean CV% 
 
Upper limit of 
normal percentage 
change   
(8) 
78 CF Children 
aged 2.5-
6 years 
Exhalyzer Da N2 6 (3 months apart) 9.4% (0.8 to 
33.7) 
 
0.57 
Median (range) 
CV% 
 
ICC  
 
(3) 
14 CF Children 
aged 5-
18 years 
Exhalyzer Da 
using Testpoint 
software 
N2 4 (1, 3, 6 and 12 months 
apart) 
0.82 
 
-21% to 25% 
ICC  
 
Limits of agreement 
percentage 
difference 
 
 
 
 
 
 
 
 
 
(9) 
56 CF Children 
and 
adults 
aged 6-
67 years 
Modified 
Innocorb 
SF6 2 (average 8 months apart 
[range 67-614 days]) 
4.3 (visit 1 vs 
4.7 (visit 2) 
 
1.4 
 
0.96 
Mean CV% 
 
 
CoR 
 
ICC 
(6,7)  
 Feasibility  
Subject type Device and 
Gas 
N measurements 
required for each 
session 
Number of 
tests 
attempted 
Number (%) of 
tests 
successful 
Reasons for 
exclusion 
Author 
CF Children 
aged 
6-17 years 
Exhalyzer Da  
N2 
At least 2 within 1 
session 
109 106/107 (99) NR (8) 
CF Children 
aged 5-18 
years 
Exhalyzer Da  
N2 
At least 2 within 1 
session 
171 168/171 (98) N=1 invalid 
N=1 only 1 valid 
trial 
(9) 
CF Children 
aged 2.5-6 
years 
Exhalyzer Da  
N2 
At least 2 within 1 
session 
412 343/412 (83) N=2 Equipment 
malfunction 
N=67 
Did not meet 
quality control 
review criteria (19) 
 
(3) 
CF Infants and 
children 
aged 2.3-12 
years 
Exhalyzer Da 
SF6 and 
sedation 
protocol  
At least 2 within 1 
session 
73 67/73 
(91.8) 
(range 78.9-
100%) 
N=3 recurrent 
sighs 
N=3 technical 
problems  
 
(15) 
Respir
atory 
diseas
e 
includi
ng CF  
Infants and 
children 
aged 2.1-
5.9 years 
Innocor SF6b At least 2 within 1 
session 
116 83/116 (73) N= 9 
noncooperation  
 
N=6 
inability to tolerate 
the noseclips  
 
n=8 lack of 
understanding  
 
(16) 
n=5 inability to 
maintain a proper 
seal around the 
mouth piece 
 
n=4 
afraid to attempt 
to the test 
CF Children 
and adults 
aged 6-67 
years 
Modified 
Innocor SF6 b 
At least 2 within 1 
session 
122 110 (90) N=6 LCI not 
repeatable  
N=6 patient 
unable to 
complete 2 trials 
due to time 
limitations or 
discomfort with 
test. 
(6) 
 
aExhalyzer D (Ecomedics AG, Duernten, Switzerland) 
bModified Innocor (Innovision, Odense, Denmark) 
COR: Coefficient of repeatability 
ICC: Intraclass correlation co-efficient 
CV: Coefficient of variation 
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